Personalis (PSNL) and Tempus AI (TEM) said Monday they have expanded their collaboration to the biopharma industry.
Tempus is the exclusive commercial diagnostic partner for Personalis' NeXT Personal Dx minimal residual disease product for broad patient adoption in breast and lung cancers, as well as for immunotherapy monitoring across all solid tumors.
The expanded collaboration allows Tempus to offer the product to pharmaceutical and biotech customers who are looking to bundle minimal residual disease testing with other Tempus offerings in a given study, the companies said.
Price: 3.90, Change: +0.08, Percent Change: +2.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。